ARTICLE | Clinical News

Protegrin IB-367 oral rinse: Phase I; Phase IIa ongoing

February 20, 2001 8:00 AM UTC

IBPI reported that in a 16-patient U.S. Phase I trial of IB-367, a single dose (9 mg) of IB-367 oral rinse reduced yeast and bacteria levels by 99 percent within 30 minutes. Levels returned to normal ...